Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Subscribe To Our Newsletter & Stay Updated
